ClinicalTrials.gg
Not yet recruitingNCT06900725LEAVE-StrokeUpdated Apr 2, 2025

Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke

A Phase 2/3 interventional study of edoxaban and Edoxaban 30 mg in Elderly, Atrial Fibrillation (AF) and Ischemic Stroke, sponsored by National Taiwan University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by National Taiwan University Hospital · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
80 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing edoxaban in Atrial Fibrillation — 5 open to participants now, 6 under way, 1 of them phase 3. edoxaban · Atrial Fibrillation.

Planned enrollment
17th of 29
300 · median 536
Started
2025
the only one that year
Phase 2/3
Only one
of the 29
Registered
28th of 29
by date

Among the 29 studies testing edoxaban in Atrial Fibrillation, this one is the 17th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 28th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

5 of the 29 studies testing edoxaban in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About edoxaban

edoxaban: first FDA approval 2015 (SAVAYSA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 80 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing edoxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

This prospectively enrolled, pragmatic randomized trial aims to investigate whether very low dose edoxaban regimen (15 mg daily) achieves similar edoxaban concentrations as low dose edoxaban regimen (30 mg daily), while maintaining a comparable risk of clinical outcomes and reducing major bleeding in elderly patients with atrial fibrillation and a history of ischemic stroke or transient ischemic attack.

Read the detailed description

Edoxaban, a factor Xa inhibitor, is used to prevent stroke or systemic thromboembolism (SSE) in patients with atrial fibrillation (AF). In elderly patients, the post-hoc analysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial showed that a low-dose edoxaban regimen (LDER, 30 mg daily) reduced the risk of major bleeding compared to the standard-dose edoxaban regimen (SDER, 60 mg daily), without an offsetting increase in SSE risk. Furthermore, the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE AF) trial demonstrated that a very-low-dose edoxaban regimen (VLDER, 15 mg daily) was more effective than placebo for elderly patients where standard anticoagulant intensity posed safety concerns. Although both LDER and VLDER appear suitable for the elderly population, data comparing these two regimens are lacking.

Specific purpose:

To investigate whether VLDER (15 mg daily) achieves similar edoxaban concentrations as LDER (30 mg daily), while maintaining a comparable risk of clinical outcomes and reducing major bleeding in elderly patients with AF and a history of ischemic stroke (IS) or transient ischemic attack (TIA) through a pragmatic randomized trial.

Study design:

The Very Low-Dose Edoxaban in Elderly Atrial Fibrillation Patients with a History of Stroke (LEAVE-Stroke) trial is a prospective, multicenter, randomized trial. Elderly patients aged ≥ 80 years with AF, a history of IS/TIA and concerns about the bleeding risk of standard anticoagulant intensity will be enrolled. Participants will be randomized to either the VLDER or LDER group.

Participant number: 120 patients (60 patients in each group). YEAR 1: Participant enrollment for the LEAVE-Stroke trial. YEAR 2: Continued participant enrollment, followed by a comparison of edoxaban concentration and clinical outcomes between two dose groups.

Study outcomes:

Primary outcome: The proportion of patients achieving edoxaban concentrations within the expected range from the ENGAGE-AF TIMI 48 trial (12-43 ng/mL at trough) at 1 month.

Secondary outcome: Major bleeding at 3 months, a composite of major bleeding, SSE or death at 3 months.

Significance: This pragmatic randomized trial will be the first to report real-world edoxaban concentrations in the VLDER group and to determine whether they are comparable to those in the LDER group. Furthermore, the study will provide insights into the short-term outcomes of VLDER in elderly patients with AF, a history of IS/TIA, and concerns about increased bleeding risk. These findings will not only inform edoxaban dosing strategies in clinical practice but also serve as a foundation for future large-scale, long-term studies to evaluate the feasibility and safety of using VLDER in this high-risk population.

Keywords: very low-dose edoxaban, elderly, drug concentration, major bleeding, atrial fibrillation

03

Conditions studied

  • Elderly
  • Atrial Fibrillation (AF)
  • Ischemic Stroke

Keywords

  • very low-dose edoxaban
  • elderly
  • drug concentration
  • major bleeding
  • atrial fibrillation
04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=80 years
  • Has been diagnosed atrial fibrillation
  • Has history of ischemic stroke or
  • Has any of the bleeding risk lists below
  • bodyweight \< 60 kg
  • \< 50 mL/min
  • history of major bleeding or gastrointestinal bleeding
  • concurrent use of antiplatelet agents (such as aspirin, clopidogrel, ticagrelor, prasugrel, cilostazol), non-steroidal anti-inflammatory drugs, amiodarone, tacrolimus, cyclosporine, dronedarone.

Exclusion criteria

Exclusion Criteria:

  • Has ever used anticoagulants, defined as:
  • warfarin therapy within 1 month before study enrollment.
  • using heparin, low molecular weight heparin or direct oral anticoagulants within 7 days before study enrollment.
  • allergy to edoxaban
  • under regular dialysis, includes hemodialysis or peritoneal dialysis
  • refuse to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    LDER

    Patients will receive edoxaban 30 mg daily for stroke prevention.

    Drug: Edoxaban 30 mg

  • Active comparator
    VLDER

    Patients will receive edoxaban 15 mg daily for stroke prevention.

    Drug: edoxaban

Interventions

  • edoxaban 15 mg daily will be administered to the patients as secondary stroke prevention.

    Also known as: VLDER

  • DrugEdoxabanStudies of EdoxabanEdoxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    edoxaban 30 mg daily will be administered to the patients as secondary stroke prevention.

    Also known as: LDER

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving edoxaban concentrations within the expected range

    The proportion of patients achieving edoxaban concentrations within the expected range from the ENGAGE-AF TIMI 48 trial (12-43 ng/mL at trough) at 1 month.

    Time frame: 1 month

Secondary outcomes

  1. Major bleeding

    Major bleeding at 3 months Major bleeding is classified according to the Platelet Inhibition and Patient Outcomes (PLATO) criteria. Major life-threatening bleeding was defined as intracranial hemorrhage, intrapericardial bleeding, or overt bleeding leading to hemorrhagic shock, hypotension requiring inotropic agents or surgical intervention, or a hemoglobin reduction of more than 5 g/dL or necessitating a transfusion of ≥4 units of packed red blood cells. Other major bleeding events were classified as significant, disabling bleeding, or bleeding resulting in a hemoglobin decrease of 3-5 g/dL requiring a transfusion of 2-3 units of packed red blood cells.

    Time frame: 3 months

  2. Composite outcome

    A composite of major bleeding, stroke or systemic thromboembolism or death. Stroke or systemic thromboembolism includes ischemic stroke (IS), transient ischemic attack (TIA), acute coronary syndrome, coronary artery disease, peripheral arterial occlusive disease, and venous thromboembolism. IS or TIA diagnoses were confirmed by brain computed tomography (CT) or magnetic resonance imaging (MRI). Brain CT angiography or perfusion was performed in patients with suspected large vessel occlusion. TIA was defined as a transient or reversible episode of neurological dysfunction lasting for \< 24 h

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2030, 68 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2025
First posted
Mar 28, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06900725
Collaborators
National Taiwan University Hospital, Yun-Lin Branch, National Taiwan University Hospital Hsin-Chu Branch
Responsible party
National Taiwan University Clinical Trial Center (Professor, National Taiwan University Hospital) — Principal investigator
First posted
Mar 28, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Apr 2, 2025

Study contacts

Shin Yi Lin, MS
Contact
shinyi924@gmail.com
886223123456

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edoxaban

Start the discussion